A krónikus mieloid leukémia molekuláris monitorozásának aktuális kérdései

Richárd Kiss, Attila Péter Király, Júlia Gaál-Weisinger, Dóra Marosvári, Péter Ambrus Gángó, J. Demeter, Csaba Bödör

Research output: Article

Abstract

The last fifteen years brought a revolution both in treatment and diagnostics of chronic myeloid leukemia. Nowadays, the main method for monitoring of the disease is molecular monitoring with real-time PCR technology which can indicate treatment modification. With the development of the international scale and inter-laboratory standardization the residual tumor mass can be measured accurately and the results are comparable between the different laboratories. By the growing experience in the field of molecular responses we can now accurately predict treatment outcome early on with the so called early molecular response and BCR-ABL1 kinetics, allowing the selection of the best TKI with the treatment-free remission representing real option of the near future. Nevertheless, further advancements can be expected, including the workflow automatization and detection of even deeper molecular responses.

Original languageHungarian
Pages (from-to)57-66
Number of pages10
JournalMagyar onkologia
Volume61
Issue number1
Publication statusPublished - márc. 8 2017

Fingerprint

Myeloid Leukemia
Workflow
Residual Neoplasm
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Real-Time Polymerase Chain Reaction
Technology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kiss, R., Király, A. P., Gaál-Weisinger, J., Marosvári, D., Gángó, P. A., Demeter, J., & Bödör, C. (2017). A krónikus mieloid leukémia molekuláris monitorozásának aktuális kérdései. Magyar onkologia, 61(1), 57-66.

A krónikus mieloid leukémia molekuláris monitorozásának aktuális kérdései. / Kiss, Richárd; Király, Attila Péter; Gaál-Weisinger, Júlia; Marosvári, Dóra; Gángó, Péter Ambrus; Demeter, J.; Bödör, Csaba.

In: Magyar onkologia, Vol. 61, No. 1, 08.03.2017, p. 57-66.

Research output: Article

Kiss, R, Király, AP, Gaál-Weisinger, J, Marosvári, D, Gángó, PA, Demeter, J & Bödör, C 2017, 'A krónikus mieloid leukémia molekuláris monitorozásának aktuális kérdései', Magyar onkologia, vol. 61, no. 1, pp. 57-66.
Kiss R, Király AP, Gaál-Weisinger J, Marosvári D, Gángó PA, Demeter J et al. A krónikus mieloid leukémia molekuláris monitorozásának aktuális kérdései. Magyar onkologia. 2017 márc. 8;61(1):57-66.
Kiss, Richárd ; Király, Attila Péter ; Gaál-Weisinger, Júlia ; Marosvári, Dóra ; Gángó, Péter Ambrus ; Demeter, J. ; Bödör, Csaba. / A krónikus mieloid leukémia molekuláris monitorozásának aktuális kérdései. In: Magyar onkologia. 2017 ; Vol. 61, No. 1. pp. 57-66.
@article{dba256932a21443a9a866576e8264135,
title = "A kr{\'o}nikus mieloid leuk{\'e}mia molekul{\'a}ris monitoroz{\'a}s{\'a}nak aktu{\'a}lis k{\'e}rd{\'e}sei",
abstract = "The last fifteen years brought a revolution both in treatment and diagnostics of chronic myeloid leukemia. Nowadays, the main method for monitoring of the disease is molecular monitoring with real-time PCR technology which can indicate treatment modification. With the development of the international scale and inter-laboratory standardization the residual tumor mass can be measured accurately and the results are comparable between the different laboratories. By the growing experience in the field of molecular responses we can now accurately predict treatment outcome early on with the so called early molecular response and BCR-ABL1 kinetics, allowing the selection of the best TKI with the treatment-free remission representing real option of the near future. Nevertheless, further advancements can be expected, including the workflow automatization and detection of even deeper molecular responses.",
author = "Rich{\'a}rd Kiss and Kir{\'a}ly, {Attila P{\'e}ter} and J{\'u}lia Ga{\'a}l-Weisinger and D{\'o}ra Marosv{\'a}ri and G{\'a}ng{\'o}, {P{\'e}ter Ambrus} and J. Demeter and Csaba B{\"o}d{\"o}r",
year = "2017",
month = "3",
day = "8",
language = "Hungarian",
volume = "61",
pages = "57--66",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - A krónikus mieloid leukémia molekuláris monitorozásának aktuális kérdései

AU - Kiss, Richárd

AU - Király, Attila Péter

AU - Gaál-Weisinger, Júlia

AU - Marosvári, Dóra

AU - Gángó, Péter Ambrus

AU - Demeter, J.

AU - Bödör, Csaba

PY - 2017/3/8

Y1 - 2017/3/8

N2 - The last fifteen years brought a revolution both in treatment and diagnostics of chronic myeloid leukemia. Nowadays, the main method for monitoring of the disease is molecular monitoring with real-time PCR technology which can indicate treatment modification. With the development of the international scale and inter-laboratory standardization the residual tumor mass can be measured accurately and the results are comparable between the different laboratories. By the growing experience in the field of molecular responses we can now accurately predict treatment outcome early on with the so called early molecular response and BCR-ABL1 kinetics, allowing the selection of the best TKI with the treatment-free remission representing real option of the near future. Nevertheless, further advancements can be expected, including the workflow automatization and detection of even deeper molecular responses.

AB - The last fifteen years brought a revolution both in treatment and diagnostics of chronic myeloid leukemia. Nowadays, the main method for monitoring of the disease is molecular monitoring with real-time PCR technology which can indicate treatment modification. With the development of the international scale and inter-laboratory standardization the residual tumor mass can be measured accurately and the results are comparable between the different laboratories. By the growing experience in the field of molecular responses we can now accurately predict treatment outcome early on with the so called early molecular response and BCR-ABL1 kinetics, allowing the selection of the best TKI with the treatment-free remission representing real option of the near future. Nevertheless, further advancements can be expected, including the workflow automatization and detection of even deeper molecular responses.

UR - http://www.scopus.com/inward/record.url?scp=85066498011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066498011&partnerID=8YFLogxK

M3 - Article

VL - 61

SP - 57

EP - 66

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -